Opioid receptors mediate the actions of endogenous and exogenous opioids on many physiological processes, including the regulation of pain, respiratory drive, mood, and-in the case of k-opioid receptor (k-OR)-dysphoria and psychotomimesis. Here we report the crystal structure of the human k-OR in complex with the selective antagonist JDTic, arranged in parallel dimers, at 2.9 Å resolution. The structure reveals important features of the ligand-binding pocket that contribute to the high affinity and subtype selectivity of JDTic for the human k-OR. Modelling of other important k-OR-selective ligands, including the morphinan-derived antagonists norbinaltorphimine and 59-guanidinonaltrindole, and the diterpene agonist salvinorin A analogue RB-64, reveals both common and distinct features for binding these diverse chemotypes. Analysis of site-directed mutagenesis and ligand structure-activity relationships confirms the interactions observed in the crystal structure, thereby providing a molecular explanation for k-OR subtype selectivity, and essential insights for the design of compounds with new pharmacological properties targeting the human k-OR.
Opioid receptors mediate the actions of endogenous and exogenous opioids on many physiological processes, including the regulation of pain, respiratory drive, mood, and-in the case of k-opioid receptor (k-OR)-dysphoria and psychotomimesis. Here we report the crystal structure of the human k-OR in complex with the selective antagonist JDTic, arranged in parallel dimers, at 2.9 Å resolution. The structure reveals important features of the ligand-binding pocket that contribute to the high affinity and subtype selectivity of JDTic for the human k-OR. Modelling of other important k-OR-selective ligands, including the morphinan-derived antagonists norbinaltorphimine and 59-guanidinonaltrindole, and the diterpene agonist salvinorin A analogue RB-64, reveals both common and distinct features for binding these diverse chemotypes. Analysis of site-directed mutagenesis and ligand structure-activity relationships confirms the interactions observed in the crystal structure, thereby providing a molecular explanation for k-OR subtype selectivity, and essential insights for the design of compounds with new pharmacological properties targeting the human k-OR.
The four opioid receptors, m, d, k and the nociceptin/orphanin FQ peptide receptor, belong to the class A (rhodopsin-like) c subfamily of G-protein-coupled receptors (GPCRs) 1 with a common seventransmembrane helical architecture, and are coupled predominantly to heterotrimeric G i /G o proteins. Activation of these receptors by endogenous or exogenous ligands is linked to a number of neuropsychiatric sequelae, including analgesia, sedation, depression, dysphoria and euphoria 2 . The three closely related subtypes, m-OR, d-OR and k-OR, share ,70% sequence identity in their seven transmembrane helices (I-VII), with more variations in the extracellular loops (ECLs) and very little similarity in their amino and carboxy termini 2 . The majority of endogenous opioid peptides have a defined preference for specific subtypes, for example, endorphins act via d-ORs and m-ORs, whereas dynorphins preferentially activate k-ORs. However, most exogenous and synthetic opioid ligands interact promiscuously (see the K i Database; http://pdsp.med.unc.edu/pdsp. php), probably owing to the high degree of similarity among binding pockets of opioid receptors. Although decades of focused medicinal chemistry efforts have yielded reasonably selective ligands for all four ORs (see the K i Database), there remains substantial interest in the development of subtype-selective agonists and antagonists.
Recent breakthroughs in elucidating high-resolution structures of GPCRs in complex with small-molecule 3-7 and peptide 8 ligands are providing details of their function 9 , leading to numerous rational ligand discovery studies 10, 11 . However, whereas most of these structures belong to the a subfamily of class A GPCRs 1 , the highly diverse peptide-binding c subfamily is represented only by the CXCR4 chemokine receptor 8 ; additional structural coverage is needed to elucidate the repertoire of features 12 that define the pharmacological profile of this subfamily. The k-OR, identified based on studies with the k-type prototypic agonist ketocyclazocine 13 , represents an attractive target for structure determination. Several k-OR-selective partial agonists and antagonists have been developed as potential antidepressants, anxiolytics and anti-addiction medications 14 , whereas a widely abused, naturally occurring hallucinogen-salvinorin A (SalA)-was also found to be a highly selective k-OR agonist 15 . Although many k-OR agonists and antagonists have not demonstrated desirable pharmacological properties, lacking specificity or displaying frank psychotomimetic actions in humans 14, 16 , some have been shown to be viable drug candidates. A k-OR ligand in early stages of clinical development, JDTic (3R)-1,2,3,4-tetrahydro-7-hydroxy-N-
methyl]-2-methylpropyl]-3-isoquinolinecarboxamide), was originally designed as a novel selective k-OR antagonist 17 that blocks the k-OR agonist U50,488-induced antinociception, while not antagonizing m-OR agonist-induced analgesia 18 . JDTic also displays robust activity in rodent models of depression, anxiety, stress-induced cocaine relapse, and nicotine withdrawal 18, 19 . Here we report the crystal structure of a human k-OR construct, k-OR-T4 lysozyme (T4L), in complex with JDTic at 2.9 Å resolution. The results provide structural insights into the atomic details of molecular recognition and subtype selectivity of the k-OR and related ORs, and should catalyse the structure-based design of advanced human k-OR agonists and antagonists with improved pharmacological profiles and enhanced therapeutic efficacies.
Overall architecture of the k-OR
Structural studies were carried out using an engineered human k-OR construct (see Methods and Supplementary Fig. 1 ) and crystallized in cholesterol-doped monoolein lipidic cubic mesophase (see Methods). The construct used showed pharmacological behaviour similar to that of a native receptor expressed in HEK293T cells (Supplementary  Tables 2 and 3 ). Data collection and refinement statistics are shown in Supplementary Table 1 .
The structure of k-OR-JDTic was determined at 2.9 Å in the P2 1 2 1 2 1 space group. The asymmetric unit consists of two receptors forming a parallel dimer (Fig. 1a ). The dimer interface with ,1,100 Å 2 buried surface area is formed through contacts among helices I, II and VIII ( Fig. 1a , insert). Previously, parallel receptor dimers have been identified in crystal structures of activated rhodopsin (involving helices I, II and VIII) 20 , the b 2 adrenergic receptor (b 2 -AR; cholesterol mediated) 3 and CXCR4 (involving helices IV, V and VI) 8 . Consistent with these crystallographic data, recent biochemical studies have suggested the existence of two dimerization interfaces: along helices IV and V (sensitive to receptor activation) and along helix I (insensitive to the state of activation) 21 . Although the orientations of the two T4L copies in the receptor monomers in one asymmetric unit differ by ,60u rotation, both copies of the receptor are highly similar ( Fig. 1b ) and will be treated identically except where otherwise noted.
The main fold of the human k-OR consists of a canonical seventransmembrane bundle of a-helices followed by an intracellular helix VIII that runs parallel to the membrane (Fig. 1a, b ), resembling previously solved GPCR structures [3] [4] [5] [6] [7] [8] . Structural comparison with other GPCRs suggests that human k-OR has marked similarities in the ECL region with CXCR4, another peptide-binding receptor in the c subfamily. In the seven-transmembrane region, however, the k-OR structure is closer to aminergic receptors belonging to the a subfamily (alpha carbon root mean squared deviation (r.m.s.d.) ,2.3 Å for the b 2 -AR, ,1.9 Å for the dopamine D3 receptor (D3R) and ,2.7 Å for CXCR4). The structure reveals distinctive features of the human k-OR, including the following. First, conformation of the extracellular end of helix I deviates from the position observed in CXCR4, where the tip of helix I is pulled towards the transmembrane bundle by a disulphide bond between the N terminus and ECL3. Second, ECL2, the largest extracellular loop of the human k-OR, forms a b-hairpin similar to that observed in CXCR4, despite the low sequence similarity in this domain between the two receptors. Conservation of this feature between these peptide receptors suggests that the b-hairpin could be a common motif in the ECL2 of other c subfamily receptors, where interactions between ECL2 and their endogenous peptide ligands are deemed important for ligand recognition and selectivity 22 . Third, unlike other solved nonrhodopsin class A GPCRs that have more than one disulphide bond, the human k-OR has only one formed between Cys 131 3.25 (superscripts indicate residue numbering using the Ballesteros-Weinstein nomenclature 23 ) and Cys 210, bridging ECL2 to the end of helix III. These two cysteines are conserved in all opioid receptors and this disulphide bond is the canonical one shared by most other solved class A GPCRs. Fourth, intracellular loop 2 (ICL2) adopts slightly different structures in the two k-OR molecules in the asymmetric unit, involving a two-turn a-helix in molecule B, and only a one-turn a-helix in molecule A ( Supplementary Fig. 2 ), possibly reflecting the conformational plasticity of this region 5 . Last, ECL3 of the k-OR is disordered.
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A common feature of the class A GPCRs is the presence of a conserved sequence motif Asp/Glu 3.49 -Arg 3.50 -Tyr 3.51 (D/ERY) located at the cytoplasmic end of helix III. A salt bridge interaction between Arg 3.50 and Asp/Glu 6.30 from the cytoplasmic end of helix VI constitutes an 'ionic lock', which is thought to stabilize the inactive conformation of rhodopsin and other rhodopsin-like class A GPCRs 5,24 , whereas its absence can enhance constitutive activity 6, 23 . Although the human k-OR lacks either of the acidic residues Asp/Glu at position 6.30, Arg 156 3.50 forms a hydrogen bond to another helix VI residue, Thr 273 6.34 (Supplementary Fig. 3a ) in this inactive k-OR structure, thereby conceivably stabilizing the inactive receptor conformation. The NPXXY motif located at the cytoplasmic side of helix VII, which is composed of Asn 326 7.49 , Pro 327 7.50 , Ile 328 7.51 , Leu 329 7.52 and Tyr 330 7.53 in the k-OR, is another highly conserved functional motif that is proposed to act as one of the molecular switches responsible for class A GPCR activation 25, 26 . Comparison of the human k-OR with inactive b 2 -AR and A 2A adenosine receptor (A 2A AR) structures ( Supplementary Fig. 3b ) reveals a similar conformation of this motif in these receptors, thereby supporting the hypothesis that the observed k-OR-JDTic complex structure corresponds to the inactive state. To establish further that JDTic stabilizes an inactive conformation, we evaluated its ability to modulate G i /G o -mediated and b-arrestin-mediated signalling in transfected HEK293T cells. We found that JDTic was devoid of agonist activity at both canonical and non-canonical pathways and completely blocked the effects of the prototypic agonist U69593 ( Supplementary Fig. 4 ).
The k-OR ligand-binding pocket
The k-OR ligand-binding pocket displays a unique combination of key characteristics both shared with and distinct from those in the chemokine and aminergic receptor families. Although the human k-OR binding pocket is comparatively large and partially capped by the ECL2 b-hairpin, as in CXCR4, it is also much narrower and deeper than in CXCR4 (Fig. 2c, d and Supplementary Fig. 5 ). In addition to a different set of side chains lining the pocket, the shape differences result from an approximately 4.5 Å inward shift of the extracellular tip of helix VI in the k-OR as compared to CXCR4. The electron density clearly shows the position of the JDTic ligand (Supplementary Fig. 6 ), which reaches deep into the pocket to form ionic interactions with the Asp 138 3.32 side chain ( Fig. 2a ). The Asp 3.32 residue is conserved in all aminergic GPCRs, thereby having a critical role in the selectivity of aminergic receptors towards protonated amine-containing ligands. Likewise, Asp 3.32 is conserved in all opioid receptors, and modelling and mutagenesis studies 27 suggest that it has an essential role in anchoring positively charged k-OR ligands.
Structural basis of JDTic selectivity
JDTic, developed as a derivative of the trans-(3R,4R)-4-(3hydroxyphenyl)-3,4-dimethyl-1-piperidine scaffold 17 , has exceptionally high affinity (K i 5 0.32 nM), potency (K i 5 0.02 nM in GTPcS assays) 17, 28 , long duration of action and a more than 1,000-fold selectivity for the human k-OR as compared to other opioid receptor subtypes 28 . Extensive structure-activity relationship (SAR) analyses performed on JDTic analogues have yielded important insights into key determinants of JDTic activity [28] [29] [30] , although reliable identification of the interaction mode(s) and contact residues of these ligands has not been feasible without a receptor crystal structure.
The crystal structure of k-OR-JDTic shows a tight fit of the ligand in the bottom of the binding cleft ( Fig. 2a ), forming ionic, polar and extensive hydrophobic interactions with the receptor (Fig. 2b) . The protonated amines in both piperidine and isoquinoline moieties of the ligand form salt bridges to the Asp 138 3.32 side chain (3.0 and 2.8 Å nitrogen-oxygen for molecule A, and 2.7 and 2.3 Å for molecule B, respectively). The piperidine amine is part of the original trans-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine scaffold and is essential for opioid receptor antagonist activity 31 . SAR studies of JDTic analogues show that the isoquinoline nitrogen can be replaced by carbon, oxygen or sulphur atoms with only a ,10-to 50-fold 
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reduction in affinity 30 . Similar to the observed JDTic conformation in the k-OR-JDTic complex, a V-shaped conformation was found in the small molecule X-ray crystal structure of JDTic, which showed its amino groups coordinating a water molecule ( Supplementary Fig.  7a ). Although several rotatable bonds within the JDTic molecule allow for the sampling of different conformations (see Supplementary Fig.  7b ) and facilitate the ligand passage through the narrow binding pocket entrance, the anchoring-type interaction of two amino groups with Asp 138 3.32 probably fixes the ligand in this characteristic V shape. SAR studies have also underscored the importance of the distal hydroxyl groups on both the piperidine and isoquinoline moieties of JDTic, the removal of which did result in about a 100-fold reduction of affinity. A much smaller effect was observed upon methylation of these hydroxyls or their replacement by other polar groups 28 . These SAR results suggest the importance of water-mediated interactions between these two hydroxyl groups and the receptor. Indeed, although the crystal structure does not show direct hydrogen bonding with the receptor for both hydroxyl groups, there is clear electron density for several structured water molecules that mediate their polar interactions ( Supplementary Fig. 6 ).
The k-OR structure provides important clues for understanding the structural basis of the exceptional subtype selectivity of JDTic. Among many extensive contacts, JDTic interacts with four residues in the binding pocket that differ in other closely related opioid receptors, which are thought to contribute to the subtype selectivity of JDTic and other k-OR-selective ligands 32 (human m-OR and d-OR amino acids are shown in parentheses, respectively): Val 108 2.53 (Ala and Ala), Val 118 2.63 (Asn and Lys), Ile 294 6.55 (Val and Val) and Tyr 312 7.35 (Trp and Leu) ( Fig. 2b and Supplementary Fig. 8 ). Analysis of JDTic binding into k-OR-based m-OR and d-OR homology models, as well as JDTic SAR results 17, 28, 30 (Supplementary Fig. 9 ), suggest that all described residues can contribute to the JDTic selectivity profile. Thus, changes in the Val 118 2.63 side chain, where larger hydrophilic residues Asn 2.63 and Lys 2.63 are found in the human m-OR and d-OR, respectively, are likely to introduce unfavourable contacts with JDTic. Additionally, changing Tyr 312 7.35 to the Trp 7.35 and Leu 7.35 residues found in the human m-OR and d-OR, respectively, is likely to result in the loss of an important polar interaction with the JDTic amide. The remaining two hydrophobic side-chain replacements, Val to Ala at position 2.53 and Ile to Val at position 6.55, may cause a reduction of the hydrophobic contact between JDTic and the receptor.
The isopropyl group of JDTic reaches deep into the orthosteric pocket to form a hydrophobic interaction with a conserved Trp 287 6.48 side chain, possibly having a critical role in the pharmacological properties of this ligand. Trp 6.48 is thought to be a key part of the activation mechanism in many class A GPCRs, including rhodopsin 26 and the A 2A AR 25 , and similar hydrophobic contacts have been implicated in blocking activation-related conformational changes in the dark state visual rhodopsin by 11-cis retinal, and by inverse agonists in the A 2A AR and D3R.
Binding of k-OR-selective morphinans
Prior mutagenesis and modelling studies suggested that many smallmolecule opioid ligands can interact with the k-OR, as well as with the m-OR and d-OR, by forming a salt bridge with the highly conserved Asp 3.32 (refs 33, 34) . This is consistent with our mutagenesis studies ( Supplementary Table 3 ) and flexible docking 35 of a series of morphine analogues, including selective k-OR antagonists norbinaltorphimine (nor-BNI) and 59-guanidinonaltrindole (GNTI) ( Fig. 3 and Supplementary Fig. 10 ). To assess the compatibility of these bulky and rigid ligands with the observed k-OR protein backbone conformation, we performed global energy optimizations of nor-BNI and GNTI in the binding cavity of k-OR, keeping side chains of the binding pocket fully flexible. Multiple independent runs consistently resulted in low energy conformations with essentially identical poses and receptor contacts for the common naltrexone moieties of both nor-BNI and GNTI (r.m.s.d. 0.85 Å ). In addition to a highly complementary van der Waals interface, both compounds formed an amino group salt bridge to the Asp 138 3.32 side chain and a hydrogen bond to the Tyr 139 3.33 side chain, both of which are important anchoring points for binding of morphine-based ligands, as supported by previous mutagenesis studies 34 .
Moreover, unlike JDTic, both nor-BNI and GNTI compounds have a second basic moiety located more than 10 Å away from the first amino group (the second morphine moiety in nor-BNI and the guanidine moiety in GNTI). In the predicted models of k-ORnor-BNI/GNTI complexes, these additional amino groups of both ligands form a salt bridge with Glu 297 6.58 located at the entrance to the ligand-binding pocket, which was previously characterized as a residue critical for subtype selectivity of k-OR-selective morphinan derivatives 36 . This interaction is also supported by our mutagenesis results ( Supplementary Table 3 ), where a Glu297Ala mutation induced a significant drop in both nor-BNI and GNTI binding affinity, but did not affect JDTic affinity. Hydrophobic interactions at the k-OR-specific residue Ile 294 were also found for both nor-BNI and GNTI; consistent with our mutagenesis results (Supplementary 
Figure 3 | Putative interaction modes of morphine-based high-affinity
k-OR-selective antagonists nor-BNI and GNTI. a, b, Interaction modes of nor-BNI (a) and GNTI (b). Ligands are depicted as capped sticks with green carbons, and contact side chains of the receptor within 4 Å from the ligand are shown with grey carbons. Key hydrogen bonds and salt bridges are indicated with small cyan spheres and residues unique to the k-OR are labelled in blue. Residue Asp 138 3.32 , which also shows critical impact on GNTI and nor-BNI binding in mutagenesis studies, is highlighted in red. Ballesteros-Weinstein residue numbers are shown under the k-OR residue numbers. The graphics were prepared using the ICM molecular modelling package (Molsoft LLC). Table 3 ) and suggesting that Ile 294 may also be important for developing human k-OR-subtype-selective morphinan derivatives. Additional polar interactions with k-OR-specific residues, Glu 209 and Ser 211 in ECL2, are found for nor-BNI, which may further enhance the k-OR selectivity of this bulky ligand. Another side chain of the pocket, His 291 6.52 , which is involved in the highly conserved aromatic cluster around Trp 6.48 and thought to have a critical role in the receptor activation process 37 , forms hydrophobic contacts with JDTic, nor-BNI and GNTI. His 291 6.52 can be mutated to another aromatic residue, phenylalanine, without disrupting binding of these antagonists (Supplementary Table 3 ). The non-conservative His291 6.52 Lys mutation, however, abolished binding of all tested ligands, probably because of the disruption of the aromatic cluster induced by the lysine side chain. Interestingly, the cyclopropyl moiety of both nor-BNI and GNTI in these binding poses has the same position as the isopropyl moiety of JDTic, making hydrophobic contact with the conserved residue Trp 287 6.48 . This cyclopropyl moiety is generally implicated in conversion of opioid agonists into antagonists (for example, agonist oxymorphone into antagonist naltrexone), and this effect may be partially explained by a direct interaction with the Trp 287 6.48 side chain.
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Overall, these structure-based docking results support the 'messageaddress' model 38 for morphine-based ligands nor-BNI and GNTI 36 , which points to Glu 297 6.58 as a key side chain that controls k-OR selectivity by anchoring the 'address' moieties of these compounds. The crystal structure of the k-OR-JDTic complex (Figs 2 and 3) , however, demonstrates that even without an 'address' interaction with Glu 297 6.58 , more than a 1,000-fold subtype-selectivity to k-OR can be achieved for JDTic and some of its derivatives. Importantly, then, the message-address hypothesis does not uniformly apply to all k-ORselective antagonists.
Binding of salvinorins
SalA, a naturally occurring diterpene from the widely abused hallucinogenic plant Salvia divinorum, represents an exceedingly potent (half-maximum effective concentration (EC 50 ) 5 1 nM) and selective k-OR agonist (.1,000-fold) 15 . SalA is unique compared to other k-OR ligands in that it lacks a charged or polar nitrogen atom to anchor it in the binding pocket. Extensive site-directed mutagenesis, substituted cysteine-accessibility mutagenesis (SCAM) and SAR studies on SalA and its analogues have been performed, indicating (among others) that the 2-acetoxy moiety interacts with Cys 315 7.38 (ref. 39) . Possible modes of interaction between the cysteine-reactive and ultrapotent agonist and SalA analogue 22-thiocyanatosalvinorin A (RB-64; K i 5 0.59 nM; EC 50 5 0.077 nM) 39 , and the human k-OR structure were thus evaluated. Exposure of k-OR to RB-64 produces irreversibly bound, wash-resistant adducts that are tethered to Cys 315 7.38 (ref. 39 ). As the thiocyanate group contains two electrophilic centres, two distinct adducts may be formed, increasing the mass by either 463 or 431 AMU. Docking studies using GOLD 40 predict that the salvinorin 2-position can access Cys 315 7.38 while maintaining many of the interactions implicated by site-directed mutagenesis for SalA, providing a possible mechanism for the formation of the k-OR-RB-64 adduct ( Fig. 4 , Supplementary Tables 4 and 5 , and Supplementary Figs 11  and 12 ). Additionally, the docking results serve as a model of the initial recognition process of SalA-related agonists of the human k-OR in an inactive state, although additional studies will be needed to fully elucidate the nature of the SalA-induced activation mechanism.
Conclusions
The k-OR-JDTic crystal structure has uncovered a combination of key features shared with chemokine and aminergic GPCRs along with unique structural details characteristic of the opioid subfamily. The human k-OR was crystallized as a parallel dimer with contacts involving helices I, II and VIII. Although the existence of GPCR dimers in vivo and their physiological relevance remain highly debatable, several distinct potential dimer interfaces are starting to emerge from crystallographic and biochemical studies. Such multiple dimerization interfaces may serve to support different functional pathways, as well as to promote oligomeric assembly of GPCRs. Analysis of ligand-receptor interactions has revealed important molecular details of the exceptionally high affinity and subtype selectivity of JDTic, a small-molecule antagonist with a broad therapeutic potential. The elucidation of a large binding cavity with a multitude of potential anchoring points begins to explain both the broad structural diversity of drugs targeting the human k-OR and differences in their receptor interaction modes, as supported by differential effects of various site-directed mutations on the binding properties of chemically diverse prototypic ligands. The human k-OR structure provides a long anticipated molecular framework for understanding opioid drug action, and thereby affords valuable new opportunities for the structure-based discovery of new drugs with ideal pharmacological properties.
METHODS SUMMARY
k-OR-T4L was expressed in Spodoptera frugiperda (Sf9) cells. Ligand-binding and functional assays were performed as described in Methods. Receptor-ligand complexes were solubilized from washed Sf9 membranes using 1% (w/v) n-dodecyl-b-Dmaltopyranoside (DDM) and 0.2% (w/v) cholesteryl hemisuccinate (CHS), and purified by immobilized metal ion affinity chromatography (IMAC), followed by reverse IMAC after cleaving N-terminal Flag-103His tags by His-tagged tobacco etch virus (TEV) protease. The purified protein solution was mixed with monoolein and cholesterol in a ratio of 40%:54%:6% (w/w) to form lipidic cubic phase (LCP) from which the receptor was crystallized. Crystals were grown at 20 uC in 45 nl protein-laden LCP boluses overlaid by 800 nl of precipitant solutions as described in Methods. Crystals were harvested from the LCP matrix and flash frozen in liquid nitrogen. X-ray diffraction data were collected on the 23ID-B/D beamline (GM/CA CAT) at the Advanced Photon Source, Argonne, using a 10 mm minibeam at a wavelength of 1.0330 Å . Data collection, processing, structure solution and refinement are described in Methods. Modelling of JDTic analogues and k-OR-selective a C210 ECL2 I290 6 
ARTICLE RESEARCH
morphine derivatives nor-BNI and GNTI was performed using ICM-Pro; SYBYL-X 1.3 and GOLD Suite 5.1 were used to model RB-64 complexes, as described in Methods.
